Skip to content
LEGN·Nasdaq·US

Legend Biotech

Legend Biotech is a biotechnology company focused on cell therapies, with its lead commercial product CARVYKTI for multiple myeloma. The company generates revenue primarily from product sales and collaboration-related income tied to this therapy.

Recent Activity

Updated Oct 17, 2026
–Legend Biotech announced that the U.S. FDA cleared its IND application for LB2501, an investigational off-the-shelf CD19/CD20 in vivo CAR-T therapy.
–LB2501 is designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion.

Past updates are part of the Pro plan.

Thematic Position

LEGN

Relationship Groups

Suppliers1
Partners1
Licensing1
Competitors18

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

entity listexport controlnational security review
BIS added PRC biotechnology entities to U.S. Entity List in 2021
SEC 20-FMar 10, 2026

The full regulatory passage is part of the Pro plan.

7 more · Regulatory and geopolitical insights are part of the Pro plan.